000 01124 a2200337 4500
005 20250517144121.0
264 0 _c20180430
008 201804s 0 0 eng d
022 _a1600-0404
024 7 _a10.1111/ane.12755
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aElkjaer, M L
245 0 0 _aTeriflunomide for multiple sclerosis in real-world setting.
_h[electronic resource]
260 _bActa neurologica Scandinavica
_cNov 2017
300 _a447-453 p.
_bdigital
500 _aPublication Type: Journal Article; Observational Study
650 0 4 _aAdult
650 0 4 _aAlanine Transaminase
_xblood
650 0 4 _aCrotonates
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aHydroxybutyrates
650 0 4 _aMale
650 0 4 _aMultiple Sclerosis, Relapsing-Remitting
_xblood
650 0 4 _aNitriles
650 0 4 _aToluidines
_xadministration & dosage
700 1 _aMolnar, T
700 1 _aIlles, Z
773 0 _tActa neurologica Scandinavica
_gvol. 136
_gno. 5
_gp. 447-453
856 4 0 _uhttps://doi.org/10.1111/ane.12755
_zAvailable from publisher's website
999 _c26995838
_d26995838